Teprotumumab for treating moderate-to-severe thyroid eye disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of teprotumumab administered subcutaneously compared to a placebo in adults with moderate-to-severe active thyroid eye disease. It is a randomized, double-masked, placebo-controlled, parallel-group trial that includes an optional open-label treatment period for participants who do not respond to the initial treatment. The primary goal is to assess the proptosis responder rate, defined as a significant reduction in eye protrusion without worsening in the other eye, after 24 weeks of treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participant must provide written informed consent.
2. Participant can be male or female and must be between the ages of 18 and 80 years, inclusive, at Screening.
3. Participant must have a clinical diagnosis of Graves' disease associated with active TED with a CAS ≥ 3 (on the 7-item scale) for the most severely affected eye at Screening and Baseline.
4. Participant must have moderate-to-severe active TED (not sight-threatening but has an appreciable impact on daily life), usually associated with 1 or more of the following: lid retraction ≥ 2 mm, moderate or severe soft tissue involvement and/or inconstant or constant diplopia. (Note: Participants with no diplopia at Baseline will be limited to approximately 25% of the total number enrolled.)
5. Participant has proptosis ≥ 3 mm from Baseline (prior to diagnosis of TED), as estimated by treating physician, and/or proptosis ≥ 3 mm above normal for race and gender.
6. Participant had onset of active TED symptoms (as determined by participant records) within 15 months prior to Baseline.
7. Participants must be euthyroid with the baseline disease under control or have mild hypoor hyperthyroidism (defined as free thyroxine \[FT4\] and free triiodothyronine \[FT3\] levels \< 50% above or below the normal limits) at Screening. Every effort should be made to correct the mild hypo- or hyperthyroidism promptly and to maintain the euthyroid state for the full duration of the trial.
8. Participant does not require immediate surgical ophthalmological intervention and is not planning corrective surgery/irradiation during the trial.
9. Women of childbearing potential must have a negative serum pregnancy test at Screening and negative urine pregnancy tests at all protocol-specified time points (ie, prior to each dose and throughout participation in the trial).
10. Participant is willing and able to comply with the protocol requirements for the duration of the trial.

Exclusion Criteria:

1. Participant has decreased best-corrected visual acuity due to optic neuropathy, defined by a decrease in vision of 2 lines on the Snellen chart (or equivalent), new visual field defect or color defect secondary to optic nerve involvement within the last 6 months.
2. Participant has corneal decompensation unresponsive to medical management.
3. Participant has a decrease in CAS of ≥ 2 points between Screening and Baseline.
4. Participant has a decrease in proptosis of ≥ 2 mm between Screening and Baseline.
5. Participant had prior orbital irradiation, orbital decompression or strabismus surgery (excluding childhood strabismus surgeries unrelated to TED/Graves' disease).
6. Participant is planning to have eyelid surgery during the trial.
7. Participant received periocular botulinum toxin injection within 12 months prior to Screening.
8. Participant has any systemic use of a steroid (IV or oral) or steroid eye drops for the treatment of TED or other conditions within 3 weeks prior to Screening. Exceptions include local administration (excluding periocular), eg, topical, intra-articular, and inhaled steroids, as well as steroids used to treat infusion reactions.

Where it's running

• Catalina Eye Care - NVISION - PPDS
  Tucson, Arizona, United States Recruiting
• Shiley Eye Center University of California at San Diego
  La Jolla, California, United States Recruiting
• Amy Patel Jain MD Inc.
  Newport Beach, California, United States Recruiting
• Chicago Oculofacial Plastic Surgery
  Chicago, Illinois, United States Recruiting
• Advanced Quality Medical Research
  Orland Park, Illinois, United States Recruiting
• KU Medical Center, University of Kansas
  Kansas City, Kansas, United States Recruiting

+4 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Amgen Call Center
• Email: medinfo@amgen.com
• Phone: 866-572-6436

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Teprotumumab N01 for adults with thyroid eye disease

  This will try Teprotumumab N01 in adults with recent-onset thyroid eye disease to see if it reduces eye inflammation and improves vision and quality of life.

  Recruiting Peking University Third Hospital · Beijing · NCT07423013

• Teprotumumab N01 vs IV steroids for active thyroid eye disease

  This trial tests whether teprotumumab N01 can help people with active thyroid eye disease better than intravenous steroids.

  Recruiting Phase 4 Innovent Biologics (Suzhou) Co. Ltd. · Shanghai, Shanghai Municipality · NCT07265258

• Teprotumumab for treating thyroid eye disease and thyroid dysfunction

  This study is testing how well teprotumumab can help people with thyroid eye disease who have serious symptoms like bulging eyes, pain, and double vision.

  Recruiting Walter Reed National Military Medical Center · Bethesda, Maryland · NCT06275373

• Imaging Comparison of 68Ga-FAPI and 68Ga-DOTATATE in Thyroid Eye Disease

  This study tests two PET imaging methods (FAPI and DOTATATE) to see which best images activity in the eyes of adults with thyroid eye disease.

  Recruiting Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT07835607

• IBI3031 in Thyroid Eye Disease (TED)

  A first-in-human test in adults with moderate-to-severe TED to see if IBI3031 is safe and tolerable when given by shot under the skin or into a vein.

  Recruiting Phase 1 Innovent Biologics (Suzhou) Co. Ltd. · Shenyang, Liaoning · NCT07622368

• AMG 732 for thyroid eye disease in a rollover, open-label study

  This study tests AMG 732 in adults with moderate-to-severe thyroid eye disease who previously did not respond or relapsed, to see if the treatment helps symptoms and is safe over a rollover period.

  Recruiting at 8 sites Phase 2 Amgen · Little Rock, Arkansas and 7 other locations · NCT07438405

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.